2023 SABCS｜前沿速递，HR+乳腺癌领域重磅研究抢鲜看！_乳腺癌

2023 SABCS｜前沿速递，HR+乳腺癌领域重磅研究抢鲜看！

2023-12-04

关键词：乳腺癌

发表评论

第46届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2023年12月5日至9日在美国得克萨斯州圣安东尼奥召开。作为乳腺癌领域规模最大、最具影响力的国际性会议之一，SABCS汇集了世界各地优秀的肿瘤学专家，促进交流探讨最新研究进展、临床实践经验，推动肿瘤诊疗创新发展。医脉通特整理了HR+乳腺癌7项重磅研究精要，以飨读者。

捷报连连：CDK4/6抑制剂治疗HR+/HER2- BC最新成果

GS03-03:Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

瑞波西利(RIB) + 非甾体芳香酶抑制剂 (NSAI) 作为 HR+/HER2− 早期乳腺癌患者的辅助治疗：NATALEE 试验的最终无侵袭性疾病生存 (iDFS) 分析

PS02-01:Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials

MONALEESA-2、-3 和 -7 试验中瑞波西利+内分泌治疗老年HR+/HER2–晚期乳腺癌患者的疗效、安全性和生活质量

RF01-03:PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study

PARSIFAL-LONG：PARSIFAL 研究中，对接受氟维司群+哌柏西利 vs 来曲唑+哌柏西利治疗的HR阳性/HER2阴性晚期乳腺癌患者的延长随访

PO5-20-04:A Phase II Study of Ribociclib and Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

瑞波西利和医生选择的内分泌疗法治疗局部复发、已切除的HR阳性HER2阴性乳腺癌的II期研究（RaPhLRR研究）

GS03-06:Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

MonarchE 试验中 HR+、HER2-、淋巴结阳性、高风险早期乳腺癌患者原发性肿瘤的基因组和转录组分析

百家齐放：免疫药物、AKT抑制剂在HR+/HER2- BC的探索之路

GS01-02:Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

新辅助帕博利珠单抗或安慰剂联合化疗，随后辅助帕博利珠单抗或安慰剂联合内分泌疗法治疗早期高危ER+/HER2−乳腺癌的III期研究：KEYNOTE-756

PS02-02:Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer

III期CAPtello-291 试验的患者报告结果，探索capivasertib联合氟维司群治疗芳香酶抑制剂耐药的HR阳性/HER2阴性晚期乳腺癌患者

小结

随着精准诊疗的不断进步，尤其是CDK4/6抑制剂等新药的好消息频出，HR+乳腺癌诊疗领域的挑战与机遇不断。今年SABCS大会上，全球各地的肿瘤领域专家学者齐聚一堂，分享了诸多HR+乳腺癌学术进展，有望指导、改变临床实践，为临床精准化诊疗提供新思路。

Ribociclib辅助治疗HR+,HER2-早期乳腺癌适应症尚未获批，本资料涉及的信息仅供医疗卫生专业人士个人学术参考，非商业用途！

审批编号：KIS0013899-40188

有效期：2024年11月30日

参考文献

                                                                1.Gabriel N. Hortobagyi, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. 2023 SABCS GS03-03.                                                            

                                                                2.Lowell Hart, et al. Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials. 2023 SABCS PS02-01.                                                            

                                                                3.Antonio Llombart-Cussac, et al. PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study. 2023 SABCS RF01-03.                                                            

                                                                4.Oana Danciu, et al. A Phase II Study of Ribociclib and Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study). 2023 SABCS PO5-20-04.                                                            

                                                                5.Nicholas C. Turner, et al. Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial. 2023 SABCS GS03-06.                                                            

                                    6.Aditya Bardia, et al. Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756. 2023 SABCS GS01-02.                                
                                                            
                                                                7.Hope S. Rugo, et al. Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer. 2023 SABCS PS02-02.

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)

收藏分享